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Abstract:  This  prospective  pilot  study  evaluates  the  potential  of  high-
resolution  fiber  optic  microscopy  (HRFM)  to  identify  lymph  node 
metastases in breast cancer patients. 43 lymph nodes were collected from 14 
consenting breast cancer patients. Proflavine dye was topically applied to 
lymph  nodes  ex  vivo  to  allow  visualization  of  nuclei.  242  images  were 
collected at 105 sites with confirmed histopathologic diagnosis. Quantitative 
statistical  features  were  calculated  from  images,  assessed  with  one-way 
ANOVA, and were used to develop a classification algorithm with the goal 
of  objectively  discriminating  between  normal  and  metastatic  tissue.  A 
classification algorithm using mean image intensity and skewness achieved 
sensitivity  of  79%  (27/34)  and  specificity  of  77%  (55/71).  This  study 
demonstrates  the  technical  feasibility  and  diagnostic  potential  of  HRFM 
with  fluorescent contrast in the ex vivo evaluation of lymph nodes  from 
breast cancer patients. 
©2010 Optical Society of America 
OCIS codes: (170.1610) Clinical applications; (170.6935) Tissue characterization. 
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1. Introduction 
Breast  cancer  is  the  most  common  malignancy  affecting  women  in  North  America  and 
Europe, with approximately 200,000 new cases treated each year in the United States alone 
[1]. Treatment that involves surgical resection of the primary tumor often includes removal of 
axillary lymph nodes. The presence of axillary lymph node metastases is the most important 
prognostic factor for the patient, and determines appropriate adjuvant therapy after surgery 
[2].  However,  axillary  dissection  is  associated  with  significant  short-term  and  long-term 
complications  including  lymphedema  and  upper  extremity  dysfunction  in  up  to  50%  of 
patients [3–6]. Identification and subsequent removal and assessment of the sentinel lymph 
node (SLN) has emerged as an alternative to full axillary dissection. This procedure has fewer 
complications than axillary dissection, however, there is potential for false negative events in 
10-15% of patients [7–12]. This could result in understaging, which impacts adjuvant therapy 
recommendations,  and  the  potential  for  regional  recurrence  in  the  axilla.  An  additional 
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surgery only identifies the presence of metastases in 50-80% of patients who have lymph node 
metastases [13]. A second surgical procedure is required when SLN metastases are identified 
on permanent histologic analysis in up to 35% of patients [14]. Therefore, additional methods 
to detect lymph node metastases intra-operatively have the potential to identify appropriate 
candidates for axillary dissection and avoid false negative events. Other clinical situations in 
which additional methods to detect lymph node metastases would be useful include patients 
with ductal carcinoma in situ for whom operative removal of the SLN remains controversial 
or  for  pre-treatment  staging  of  the  axilla  in  patients  who  are  candidates  for  neoadjuvant 
chemo- and endocrine therapy. 
Current  diagnostic  approaches  rely  on  optical  imaging  of  stained  cytological  or 
histological  specimens.  Recent  advances  in  optical  imaging  and  optically  active  contrast 
agents  allow  high-resolution  imaging  of  cell  morphology  and  tissue  architecture  in  vivo 
without the need for resection [15,16]. High-resolution fiber optic microscopy (HRFM) is a 
new imaging technology that when used together with a fluorescent contrast agent, enables 
real time visualization of tissue with sub-cellular resolution in vivo. Proflavine is a fluorescent 
dye  that stains nuclei [17]. HRFM  with proflavine application has been  investigated as a 
diagnostic tool to distinguish benign from malignant tissue in the oral cavity and esophagus 
[18,19].  HRFM  with  proflavine  staining  has  the  potential  to  image  cellular  morphologic 
changes that are critical in the pathologic evaluation of lymph node metastases by exploiting 
the  cell/nucleus  size  difference  between  carcinoma  and  lymphoid  cells.  Traditional 
histopathological analysis of lymph nodes in breast cancer patients identifies epithelial cell 
clusters,  which  are  enlarged  and  crowded  compared  to  normal  lymphocytes,  are 
hyperchromatic with hematoxylin and eosin (H&E) staining, and have an increased nuclear to 
cytoplasmic  ratio  [20].  In  patients  who  have  received  preoperative  chemotherapy,  lymph 
nodes can contain stromal fibrosis and individual tumor cells may be embedded within the 
fibrosis. 
The goal of this prospective study was to evaluate the potential of HRFM with proflavine 
staining for the detection of lymph node metastases in breast cancer patients. While this study 
was performed ex vivo as a proof of concept, HRFM with proflavine staining may eventually 
be performed in vivo and thus could play an important role in clinical management of breast 
cancer patients, particularly for intra-operative assessment of lymph nodes in patients with 
early disease or for pre-treatment staging of the axilla. 
2. Methods 
The high-resolution microendoscope has previously been described in detail [18]. The HRFM 
instrument uses a light emitting diode (LED) with excitation light centered at 455 nm to excite 
proflavine fluorescence. A fiber-optic bundle composed of 30,000 fibers with a center-to-
center spacing of approximately four µm transmits the light and is placed in direct contact 
with the surface to be imaged. The field of view comprises a circle that measures 750 µm in 
diameter. The system achieves a lateral resolution of 4.4 µm, sufficient to resolve individual 
cell  nuclei.  Figure  1  shows  an  optical  diagram  of  the  battery-powered  HRFM  instrument 
along with a photograph demonstrating the small size and portability of the instrument. The 
system can be assembled for $4,500. 
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Fig.  1.  (a)  Optical  diagram  of  the  high-resolution  microendoscope  (b)  Photograph 
demonstrating the small size and portability of the battery-powered instrument. 
2.1 Clinical study 
Women  18  and  older  undergoing  surgery  for  breast  cancer  that  included  a  SLN  biopsy 
followed by complete axillary lymph node dissection were eligible to participate in this study. 
Patients enrolled in this study gave written informed consent to participate, and the study was 
reviewed and approved by the institutional review boards at two academic institutions. To 
comply with HIPAA policies, patient data were labeled by accrual number. 
Three to four representative fresh lymph node specimens were taken from each patient and 
prepared  for  imaging.  To  ensure  that  images  were  taken  of  areas  representing  normal 
lymphoid tissue and tumor metastases, a dedicated breast pathologist selected one lymph node 
that was grossly normal and one lymph node that showed gross metastasis. Other lymph nodes 
selected  for  imaging  were  grossly  ambiguous.  For  some  patients,  all  the  lymph  nodes 
appeared  normal;  in  these  cases  three  normal  appearing  nodes  were  imaged.  A  dedicated 
breast pathologist bisected each node to facilitate lymphoid tissue imaging. 
Each lymph node was photographed and imaging sites were marked on the photograph to 
serve  as  reference  points  for  histopathological  correlation.  A  0.01%  solution  (w/v)  of 
proflavine hydrochloride (Sigma-Aldrich Corp., St. Louis, MO) was topically applied to the 
cut surface of the lymph nodes for approximately ten seconds. The fiber bundle of the HRFM 
instrument was placed in direct contact with the surface of the node for imaging. Multiple 
images  were  acquired  from  adjacent  fields  of  view  at  each  location  on  the  specimen  by 
translating the probe position approximately 1 mm. On average, three nodes could be imaged 
at approximately ten sites within ten to fifteen minutes. Following imaging, the nodes were 
submitted for routine processing and H&E staining in specially labeled cassettes to facilitate 
direct  imaging–histopathological  correlation.  A  dedicated  breast  pathologist  reviewed  the 
axillary lymph nodes for metastases, and the final histopathological diagnosis was used as the 
gold  standard  for  each  imaging  site.  Imaging  sites  with  unequivocal  histopathological 
correlation were included in further analysis. 
2.2 Image analysis 
Each image was reviewed to determine that quality control criteria were met. Images with 
motion artifacts or inadequate contact between fiber bundle and tissue were excluded from 
analysis. Each image that passed quality control was analyzed to identify quantitative features 
that could be useful to distinguish normal lymphoid tissue from metastases. Because adipose 
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adipocytes and obtain a rectangular shaped field containing nuclei of lymphocytes or tumor 
cells. The dimensions of this field were variable because the region of each image containing 
nuclei of interest was also variable. A reference standard (captured in each image) was used to 
normalize pixel intensity values of the green channel of each corresponding image to account 
for  any  potential  day-to-day  variation  in  the  HRFM  instrument  and  to  allow  comparison 
between images with different exposure times. 
Five image features were calculated from each normalized region (Matlab, Mathworks, 
CA). These features included: mean image intensity, standard deviation of image intensity, 
skewness, kurtosis, and entropy. Mean image intensity was selected as a feature that may be 
useful  to  separate  normal  lymphoid  tissue  from  metastatic  tissue  because  malignant  cells 
crowd together, are enlarged, and are hyperchromatic with H&E stain. Since proflavine stains 
nuclei, images containing malignant cells may have a higher intensity than images of normal 
lymphatic tissue. The remaining four features describe variations in pixel intensity throughout 
the image and were evaluated because the disruption of tissue architecture that occurs with 
metastasis  may  also  alter  the  distribution  of  pixel  intensity  values.  Standard  deviation 
describes the spread of pixel values relative to the mean; high values of standard deviation 
correspond  to  a  wider  image  histogram  with  a  wide  range  of  pixel  intensities.  Skewness 
describes asymmetry of the image histogram and indicates if pixel values are concentrated at 
low or high values. Positive skewness on a histogram occurs when there are more low values 
than high, negative skewness when there is a concentration on high values, and zero skewness 
describes a symmetric histogram. Kurtosis describes the peakedness of an image histogram 
and  is  sensitive  to  the  size  of  the  histogram  tails.  Entropy  is  a  statistical  measure  of 
randomness that can be used to characterize the texture of an image. High values of entropy 
indicate greater randomness while low values of entropy result from a more uniform image. 
Each of these investigated features represents an objective, quantitative metric for assessing 
pixel intensity and distribution in an image. 
Since multiple images of adjacent fields of view were obtained at each site in order to 
increase the region surveyed, the feature values calculated for each image were grouped by 
site and then averaged. A one-way ANOVA test was performed to compare average feature 
values from sites containing normal lymphoid tissue and sites containing metastases. For each 
feature,  a  classification  algorithm  was  developed  using  linear  discriminant  analysis  to 
discriminate between normal lymphoid tissue and lymph nodes containing metastases, using 
histology as the gold standard. Because this was a pilot study with a relatively small number 
of measurements, the same data set was used to train the algorithm and test its performance. 
Sensitivity and specificity of classification were calculated for each of the five features. A 
receiver operator characteristic (ROC) curve was constructed and the area under the curve 
(AUC) was recorded. The two features with the best individual diagnostic performance were 
identified, and classification performance was also assessed when these two features were 
used together. 
3. Results 
A  total of 43 lymph  nodes  were collected  from 14 patients for imaging  with HRFM; 13 
patients had three nodes imaged and one had four nodes imaged. Of the 43 lymph nodes, 27 
were normal and 16 were positive for metastases according to histopathology. A total of 126 
independent sites were marked for diagnosis; at 105 of these sites the image was correlated 
with the histopathological diagnosis. 242 distinct images with adjacent fields of view were 
collected at these 105 sites. Of these images, 150 were of normal lymphoid tissue and 92 were 
of sites with metastases. Table 1 shows the distribution of data. 
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Cancer Patients 
 
Histologically 
Normal 
Histologically 
Metastatic  Total 
Axillary Lymph Nodes  27  16  43 
Independent Sites with Histological Diagnosis  71  34  105 
Images from Adjacent Fields of View  150  92  242 
Figure 2 contains an HRFM image in which both adipose and lymphoid tissue are visible 
[Fig. 2(a)]. Adipocytes display a characteristic lobular structure, while lymphocytes are very 
small and more densely packed. Figure 2(b) shows the green channel of the field that was 
used to calculate feature values; the region containing adipocytes is cropped out. Figure 2(c) is 
the corresponding histology image. 
 
Fig.  2.  (a)  High-resolution  fiber  optic  microscopy  (HRFM)  image  taken  with  from  a 
histologically normal lymph node in a region containing both adipocytes and lymphocytes after 
application of proflavine to highlight cell nuclei (b) Green channel of the image after cropping 
to remove adipocytes; quantitative features were calculated from this region (c) Corresponding 
histology  at  this  site  shows  a  normal  lymph  node.  Capsule  is  thin  and  unremarkable.  Fat 
surrounds the node. The node is populated with uniform, small, round lymphocytes. 
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Figure 3(a) shows the photograph of three bisected nodes with eight imaging sites marked in 
blue for subsequent pathologic correlation. After examining the corresponding H&E slides, a 
dedicated breast pathologist determined that the node on the left was positive for metastases, 
with  a  negative  periphery.  The  node  in  the  middle  was  negative  for  metastases.  Images 
collected from both of these nodes could be used in image analysis because the measurement 
site  could  be  correlated  to  a  histopathology  gold  standard.  The  node  on  the  right  was 
determined  to  be  positive  with  very  small  subtle  occasional  single  tumor  cells  with  no 
dominant  mass.  Images  from  this  node  were  not  used  in  further  analysis  because  it  was 
difficult to determine if HRFM measured a site containing a few tumor cells or not. Figure 
3(b) shows representative HRFM images collected at Sites 4 and 7 in the photograph. The 
HRFM image from site 7 has larger, more crowded nuclei and the average image intensity is 
greater as a result. The HRFM image from site 4 has smaller nuclei that are spaced farther 
apart; the average image intensity is lower because the cells are not as densely packed. The 
corresponding H&E images for these sites are shown in Fig. 3(c). The H&E image of site 7 
indicates  nests  of  tumor  cells,  while  that  of  site  4  shows  a  normal  node  with  sinus 
histiocytosis.  Figure  3(d)  depicts  the  image  histograms  that  were  obtained  for  each  field 
shown  in  Fig.  3(b).  The  red  histogram  corresponds  to  the  image  obtained  from  site  7 
(metastatic), while the blue histogram corresponds to the image obtained from site 4 (normal 
lymphoid tissue). Calculated feature values for each image are indicated. The metastatic site 
has a higher mean intensity than the normal site as seen by the shift in the center of the image 
histogram.  Low  skewness  is  noted  in  the  metastatic  site,  indicating  a  more  symmetrical 
histogram, while high skewness is noted in the normal site as a result of more pixel values 
concentrated at lower intensities with a long tail at higher intensity values. Kurtosis is higher 
for the normal site as seen by the sharp, high peak in the histogram, while the histogram of the 
metastatic site has a broader peak with lower kurtosis. The metastatic site has higher entropy, 
which indicates that the image is more random than the normal site. Standard deviation is 
higher in the metastatic site as seen by the wider distribution of pixel values around the mean 
as compared to the normal site. 
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Fig. 3. (a) Photograph of three lymph nodes from a single patient with imaging sites marked in 
blue for correlation to pathology (b) HRFM images collected from sites 7 and 4 with cropped 
region of interest indicated: site 7 contains metastases while site 4 is normal lymphatic tissue 
(c) Corresponding H&E images for these sites: The image from site 7 shows that metastatic 
carcinoma has replaced part of the lymph node. Dense fibrosis surrounds the metastatic tumor 
cells. Insert shows high power magnification (40X) of tumor cells. The neoplastic cells are 
arranged in nests and have amphophilic, vacuolated cytoplasms and prominent nuclei. The 
image  from  site  4  shows  a  normal  lymph  node  with  sinus  histiocytosis.  The  lymph  node 
capsule is thin and the sub-capsular sinus contains reactive histiocytes. (d) Image histograms 
from each region of interest; site 7 is shown in red while site 4 is shown in blue. Calculated 
feature values for each image are also indicated. 
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boxes represent feature values from sites containing metastases, while blue boxes represent 
normal sites. All feature values were normalized to the median value of the normal lymphoid 
tissue set in order to show the range of values on a consistent scale. P-values from a one-way 
ANOVA test for each feature are also included in Fig. 4, and the features are listed in order 
from lowest p-value to highest. The average feature values of normal lymphoid tissue are 
statistically  significantly  different  from  the  feature  values  of  metastatic  tissue  for  all  five 
features (p < 0.05). 
 
Fig. 4. Box plots showing feature values for images separated by diagnostic category. Values 
from images containing normal lymphatic tissue are shown in blue, while values from images 
containing metastases are red. All values are normalized to the median value of the normal set 
in order to show all features on the same scale. P-values obtained from a one-way ANOVA test 
are listed for each feature. 
Table 2 ranks the diagnostic performance of each of the five image features by linear 
discriminant analysis, listed in order from highest to lowest AUC. Mean image intensity and 
skewness were the two highest performing features, each with an AUC of 0.81. This order of 
performance is consistent with the p-values for each feature (Fig. 4). 
Table 2. Feature Performance 
  Quantitative Feature  Sensitivity  Specificity  AUC 
1  Mean image intensity  82% (28/34)  69% (49/71)  0.81 
2  Skewness  85% (29/34)  66% (47/71)  0.81 
3  Kurtosis  71% (24/34)  73% (52/71)  0.76 
4  Entropy  59% (20/34)  76% (54/71)  0.70 
5  Standard deviation  65% (22/34)  65% (46/71)  0.64 
Figure 5 illustrates results when the top performing two individual features, mean image 
intensity and skewness, were combined. Figure 5(a) shows a scatter plot of mean intensity 
versus  skewness  for each image; both  features provide discriminatory ability.  Figure  5(b) 
shows the ROC curve for the algorithm developed using both features. The resulting AUC 
improved to 0.84. At the Q-point of the ROC curve, sensitivity and specificity with this two-
feature algorithm were 79% (27/34) and 77% (55/71), respectively. An AUC value of 0.85 
was obtained when the data were randomly divided into training and test groups by patient, 
with all images from a specific patient assigned to either testing or training. This simulates the 
process of collecting a training group to train the algorithm, and then collecting a separate 
patient set for testing, so it is encouraging that the performance is nearly identical to the 
results obtained when the entire data set was used for both training and testing. Although 
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were used in combination, this would likely result in overtraining of the algorithm due to the 
small size of the data set from this pilot study, and so the algorithm was limited to only two 
combined features. 
 
Fig. 5. (a) Scatter plot by site of mean intensity and skewness: normal sites are shown as a blue 
‘x’  while  metastatic  sites  are  shown  as  a  red  square.  (b)  ROC  curve  obtained  from  a 
classification  algorithm  using  linear  discriminant  analysis  with  both  mean  intensity  and 
skewness as features 
4. Discussion 
This  pilot  study  demonstrates  the  technical  feasibility  of  ex  vivo  HRFM  with  proflavine 
contrast enhanced fluorescence imaging to visualize cell nuclei in axillary lymph nodes from 
breast cancer patients. These preliminary results demonstrate encouraging diagnostic potential 
of  this  fluorescence  molecular  imaging  modality  to  identify  lymph  nodes  containing 
metastases.  Using  the  image  features  of  mean  intensity  and  skewness,  a  classification 
algorithm separating normal lymphoid tissue from tissue containing metastases was developed 
that could achieve an AUC of 0.84. This compares with the reported sensitivity and specificity 
of current standard preoperative sonographic methods of evaluating axillary nodes; a recent 
review  of  16  published  studies  described  sensitivity  ranging  between  49  and  87%,  and 
specificity between 56 and 97% [21]. One comparative advantage of optical imaging is the 
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disease. 
Differences observed in these image features are consistent with qualitative differences 
observed  between  images  from  normal  lymphoid  tissue  and  metastatic  regions.  Images 
obtained  from  metastatic  sites  appear  brighter  (higher  mean  image  intensity)  than  images 
obtained from normal lymphoid tissue. This is due to the enlarged, crowded nuclei present in 
tumor cells, while normal lymphocytes have small nuclei that are spaced further apart. Higher 
mean  intensity  may  also  reflect  the  higher  occurrence  of  diploidy  and  multiploidy  and 
increased genetic material in cancer cells. Because images of normal lymph nodes have nuclei 
that are spaced further apart, there are more dark pixels, resulting in a positive skewness. 
Images of metastatic nodes have fewer low pixel values due to crowding and enlargement of 
nuclei  and  therefore  have  lower  skewness.  Calculations  to  determine  mean  intensity  and 
skewness  of  an  image  can  be  performed  extremely  rapidly,  potentially  allowing  a 
classification prediction in near real time. The step of cropping the image is critical for quality 
control, as acellular regions of fibrosis or folding of the tissue were occasionally observed to 
also display brighter fluorescence signal. This demonstrates why the high resolution imaging 
itself is important; simple intensity measurements would not be able to distinguish between 
tissue types. Though choosing a region that contains only nuclei could potentially introduce 
some user bias, this step prevents some false positive results. 
While this pilot study demonstrates encouraging results regarding the technical feasibility 
of HRFM with proflavine to visualize cell nuclei in axillary lymph nodes from breast cancer 
patients and the diagnostic potential of HRFM with proflavine to differentiate benign from 
malignant  axillary  lymph  nodes  using  quantitative  image  features  of  mean  intensity  and 
skewness, future studies are needed to evaluate the diagnostic performance of the imaging 
method in a larger, independent validation set of patients. Additional improvements to this 
technique include increasing the size of the fiber bundle to twice the current diameter, thereby 
increasing the field of view four-fold. Expanding the area that can be optically interrogated 
could improve the ability to detect metastatic cells by more efficiently imaging a lymph node 
with  decreased  imaging  time.  Future  clinical  studies  will  also  attempt  to  determine  the 
minimum size of metastasis that can be detected with this system. 
The prognostic relevance of  isolated tumor cells and  micrometastases in  lymph  nodes 
from patients  with breast cancer has become a  major area of interest in tandem  with the 
increased identification of this low volume disease due to the practice of SLN biopsy [22]. 
There  is  also  heightened  interest  in  the  evaluation  of  the  SLNs  after  neoadjuvant 
chemotherapy,  where  the  proportion  of  micrometastases  is  reportedly  higher,  and  the 
performance of intraoperative imprint cytology of SLNs is proportionately lower [23]. 
Many  functional  and  molecular  imaging  techniques  are  being  challenged  to  detect 
metastatic disease at the microscopic level in SLNs [24–26]. Noninvasive, non-ionizing, and 
high-resolution mapping of SLNs in conjunction with minimally invasive techniques, such as 
fine needle aspiration biopsy, is currently being investigated in multiple active preclinical 
protocols. While HRFM has good spatial resolution and high collection speed using current 
instrumentation, the current limitation for in vivo HRFM of lymph nodes is depth penetration. 
A potential resolution to this limitation is the in situ delivery of HRFM (i.e. endoscopy via a 
biopsy  needle)  for  real-time  in  vivo  interrogation  of  lymph  nodes  that  are  assessed 
preoperatively  with  ultrasound.  The  additional  costs  of  performing  imaging  and  imaging-
guided biopsies may be balanced on average by cost savings from avoiding SLN evaluations 
for  patients  with  documented  nodal  metastases  preoperatively  [27].  An  aspect  of  this 
technique that may limit speed of translation to the clinic is the necessary approval process 
from the United States Food and Drug Administration (FDA) to use proflavine in human 
subjects.  However,  these  pilot  studies  are  necessary  to  provide  the  foundation  for  future 
pursuit of human trials. Optical imaging can be performed very rapidly, allowing a large area 
to be surveyed in a short time, making it an attractive technology for this application. An 
advantage of optical imaging over traditional histopathology is that this rapid imaging can be 
performed in vivo. However, the intent of this technology is to augment current standards of 
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future  may  be  best  suited  for  intra-operatively  identifying  candidates  for  full  axillary 
dissection, thus preventing the need for a second surgery in some patients, or for preoperative 
staging of axilla. 
These preliminary results demonstrate the technical feasibility and diagnostic potential of 
quantitative  molecular  imaging  using  HRFM  with  proflavine  fluorescent  staining  to 
discriminate between normal and metastatic axillary lymph nodes ex vivo in breast cancer 
patients.  This  rapid  technique  is  simple,  inexpensive,  and  can  potentially  be  exploited  to 
augment  patient  care  by  providing  an  alternative  technique  for  the  detection  of 
micrometastases while requiring fewer resources and expertise. 
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